Abstract 5340
Background
HGSOC is known to demonstrate diverse molecular heterogeneity. It is unclear whether the tumor microenvironments such as the stromal components in the extracellular matrix (ECM) also exist heterogeneity.
Methods
As a proof-of concept study, characterization of collagen patterns was performed on 60 unstained formalin-fixed paraffin embedded (FFPE) HGSOC samples (three sections from each of the 20 patients). Each section with 5 micron thickness and a minimum tumour surface area of 40 mm2 were scanned by using a multiphoton imaging system (Genesis 200, HistoIndex) following deparaffinization. Parameters including Collagen Area Ratio (CAR), Collagen Fiber Density (CFD), Collagen Reticulation Index (CRI), Collagen Fiber Number (CFN), Collagen Fiber Thickness (CFT), and Collagen Fiber Length (CFL) were analysed. Unsupervised hierarchical clustering analysis was performed.
Results
Unsupervised hierarchical clustering of the collagen parameters revealed four distinct patterns in HGSOC samples. G1 tumors consisted of long and thick collagen fibers with high CFT and CFL. G2 tumors were low in all the collagen parameters, suggesting a relatively “clean” stromal without collagen deposition. G3 tumors consisted of dense collagen fibers with high CRI suggestive of extensive cross alignment among the fibers. G4 tumors were high in CFN and low in CRI, CFT and CFL, suggesting a stroma loaded with high amount of thin and short collagen fibers without cross alignment.The collagen patterns were not exclusive for specific organ sites (ovary, fallopian tube, other metastatic sites) except that the collagen pattern from the omental metastases were mainly G2 (10/18; 55.6%) and G4 (6/18; 33.3%).
Conclusions
The stromal component in the ECM of HGSOC can be successfully quantitated by the multi-photon imaging technology on unstained FFPE sections. The collagen component exhibited significant heterogeneity in terms of the number, thickness, length, and reticulation patterns. The contribution of different collagen patterns to clinical outcomes and the correlation with known molecular subtypes in HGSOC warrants further investigation in larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Singapore.
Funding
National Medical Research Council of Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract